Replimune (REPL)

[jondoeuk]

The company will host an investor event in March. The event will review updated data from completed IGNYTE cohorts in non-melanoma skin cancers and melanoma. In addition, they intend to present initial data from the ongoing study in anti-PD1 failed non-melanoma skin cancers and from its ARTACUS trial. Also, will provide a detailed overview of its RP2/3 program, including the PhII trial (around mid-year) development plan. For RP2, an update later this year. With RP3, enrolment in combination with Opdivo should start this quarter, with initial expansion patient data later this year as well.